Ayu Life Sciences Launches AED33 Million Manufacturing Facility in Jafza
Spanning 13,500 square metres, the new site will produce next-generation medical solutions, including artificial skin and antimicrobial dressings, aimed at meeting surging global demand for sustainable healthcare products. Phase 1 of the project is scheduled to be operational by late 2025, with full completion expected by 2027.
The facility will manufacture Ayu Life Sciences' key products: Velgraft™, a skin substitute for scar-free healing; Velvert™, a wound care dressing that prevents infection; and VelNez™, a post-surgical nasal and ear dressing. These products are backed by 22 global patents and developed using eco-friendly, natural materials.
The move comes as the artificial skin market is projected to grow from US$3.1 billion in 2024 to US$5.3 billion by 2032. Ayu Life Sciences currently exports to over 20 countries from its Delhi base, serving some of the world's most tightly regulated healthcare markets.
The company is also advancing research in regenerative medicine, with clinical trials underway for a potential Type 1 diabetes therapy and a treatment for peripheral nerve injuries.
Dr. Rajan Datt, Managing Director of Ayu Life Sciences, called the Jafza expansion a 'major milestone,' highlighting Dubai's strategic value in scaling access to innovative care across the Middle East and beyond.
Abdulla Al Hashmi, COO of Parks & Zones at DP World GCC, noted that the move underscores Dubai's growing role in advanced medical manufacturing and reinforces Jafza's position as a launchpad for global healthcare innovation.
News Source: Dubai Media Office
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
an hour ago
- Al Etihad
Tensions over tariffs threatening to disrupt Indo-US relations
17 Aug 2025 22:44 By Abdul Hadi*Following the collapse of the Soviet Union, US-India relations were stable and expanding until President Donald Trump imposed tariffs of up to 50% on Indian imports, which strained move came after months of failed negotiations over tariffs and was exacerbated by New Delhi's continued reliance on Russian oil in defiance of Western sanctions on Moscow over the war in decision reflected Washington's effort to pressure countries trading with Russia, and it was consistent with the 'America First' policy, which seeks to reshape global trade in ways that favour American products and strengthen domestic relations improved in the 21st century after decades of Cold War tensions. The civil nuclear energy cooperation in 2005 marked a major milestone, under which the US Nuclear Suppliers Group granted India a concession to start civilian nuclear the years that followed, the US-India security partnership deepened, driven by growing shared concerns over China's expanding presence in South Asia and the Indian the defence sphere, the United States is a major arms supplier to India. In 2016, Washington designated India as a 'major defence partner'. Between 2016 and 2019, the two countries signed several defence cooperation 2020, the United States and Australia expanded their geographical definitions of the Indian and Pacific Oceans to match those of India and Japan. This development followed trilateral dialogues among India, Japan, and the United States, as well as quadrilateral discussions involving India, Japan, the US, and establishment of a '2+2' dialogue between the foreign and defence ministers of India and the US, along with joint military exercises and manoeuvres, further deepened the strategic partnership within the Quad have come under strain after Washington imposed a 25% tariff on Indian goods, which was on expected lines, but the possibility of an additional 25% increase as sanctions for buying Russian oil by the end of August is very would rank among the highest tariff rates imposed on any US trading partner. Meanwhile, bilateral trade exceeded $128 billion in 2024, with India enjoying a surplus of about $46 billion, a trade imbalance that the US president is seeking to has responded calmly to US policies and statements while defence relations between New Delhi and Washington remain on a cooperative path. The 21st session of the annual joint 'Yudh Abhyas' ('War practice' in Hindi) military exercises is expected to take place from September 1-14 in reflects a bilateral vision based on each side securing certain gains while navigating trade issues. While the Indian government has said it will look after its own interests in buying cheaper oil from Russia, 'America First' policy also continues to be the Trump administration's tariff agreement seems to be faltering due to the nature of India's economic activities, particularly in the agricultural sector, which employs nearly 40% of the country's initial 25% tariffs will affect more than one-third of Indian exports to the US, including pharmaceuticals, automotive products and electronics. The measures would harm the competitiveness of India's major exports, especially agriculture, textiles, gemstones and is one of the world's largest emerging economies and relies heavily on oil imports to meet more than 85% of its energy needs. Washington remains a key partner for India in technology, defence, and Delhi's ties with Moscow are not an endorsement of the war but rather driven by its need for Russian crude, which has also contributed to stabilising global energy is pursuing a diplomatic course in its efforts to strike a delicate balance between its national interests and international pressures, and negotiations are still on. Trump, for instance, has said Apple's iPhones, which are being made in India, will be tariff agreement will depend on the ability of US and Indian negotiators to reach compromises that preserve their partnership. However, US policies could create more rifts in their bilateral relations, particularly if the two sides fail to agree on an alternative to the 50% rate. New Delhi may be forced to look for other allies and options. *The writer is a columnist of TRENDS Research & Advisory
The National
2 hours ago
- The National
Scientists comb through research for milestone cure for male baldness
Benjamin Franklin, one of the founding fathers of the US, famously joked that two things in life were certain: death and taxes. For many men, however, a third inevitability looms – baldness. In June, Pelage Pharmaceuticals announced 'positive results' from Phase 2a clinical trials of PP405, a drug which aims to combat male-pattern baldness and the thinning of hair in women. The drug is designed to 'reactivate dormant hair follicle stem cells' and could become a 'first-in-class' treatment for men and women, Pelage Pharmaceuticals said in a statement. The treatment could 'go beyond slowing the hair loss process and directly drive hair follicle regeneration,' said Dr Christina Weng, the company's chief medical officer. 'This is a milestone that expands the possibilities of regenerative medicine,' she added. 'As we advance into the next stage of clinical development, our focus remains on delivering a science-driven solution that works for everyone.' Trial results show encouraging signs The phase 2a trials involved 78 participants - men and women – with each person applying the drug or a placebo to their scalp once a day for four weeks. According to the results published by the company, four weeks after the treatment finished, an increase in hair density of 20 per cent or more was seen in almost one third of men who had a greater degree of hair loss. No improvement was observed in the placebo group. Pelage Pharmaceuticals says what is particularly significant is the drug's apparent ability to kick-start hair growth in follicles where no hair was previously present. A new approach to hair regeneration PP405 has been developed by researchers at the University of California, Los Angeles (UCLA), and targets a series of chemical reactions in cells. Male-pattern baldness is largely caused by genes, although environmental factors also play a role. In some men, it begins in their late teens, with rates increasing with age. A US study found that 16 per cent of men aged 18 to 29 had 'moderate to extensive' hair loss, while among 40-somethings the figure was 53 per cent. Over their lifetime, 80 per cent of men will experience hair loss. Also, about 40 per cent of women will be affected by a thinning of their hair cover. Dr Bharat Pankhania, a senior clinical lecturer at the University of Exeter Medical School, said that with respect to medication, 'some progress' had been made with male-pattern baldness. 'It's inducing the hair follicles to be stimulated to wake up and start doing things they used to do once upon a time,' he said. A true cure, however, remains elusive. Indeed, a 2023 paper in Trends in Biotechnology said that the most effective treatment remained a hair transplant. This paper noted that 'the needs and expectations of patients' were typically not met by current drug treatments, which were often expensive and had limited effectiveness. According to the study, only two drugs approved by the US Food and Drug Administration have been marketed as treatments following four decades of research – and these were branded as being only 'marginally effective'. A lucrative market driving innovation According to figures quoted in the Trends in Biotechnology paper, the global alopecia market was worth $7.6 billion in 2020, and by 2028 is likely to reach $13 billion. Some estimates have put the sector's value as being even higher. 'Because it's a huge market there's a lot of research to find a solution,' Dr Pankhania said. 'I remain optimistic, just as I remain optimistic with the management of [other conditions including] sickle cell anaemia. There's a demand.' While PP405 has sparked many headlines, there are many other strands of research aimed at gaining a better understanding of male-pattern baldness in the hope of finding a cure. Much of this centres on the genetic basis for the condition. Research by the University of Bonn and other institutions in Germany, published in 2023, found a link between rare variants of five genes and male-pattern baldness. The results, the university said when its findings were released, could lead to improved treatments. So for those whose hair is thinning or has almost completely gone, there are causes for optimism – assuming, of course, that they feel that their baldness needs to be cured.
Dubai Eye
3 hours ago
- Dubai Eye
GCC countries' gross national income hits $2.143 trillion
The Gulf Cooperation Council (GCC) countries saw a slight decline in overall national income in 2023, but their non-oil economies continued to grow steadily, according to new data from the Statistical Centre for the Cooperation Council for the Arab Countries of the Gulf (GCC-Stat). The region's Gross National Income (GNI) which reflects the total income earned by citizens and companies at home and abroad—stood at US$2.143 trillion in 2023. That marks a 2.7% drop compared to US$2.202 trillion in 2022. The disposable national income, which reflects the amount available for spending or saving after taxes and transfers, also fell by 3% to US$1.989 trillion, down from US$2.051 trillion in the previous year. Despite the dip in national income, the non-oil sector emerged as a stronger player in the region's economy. It added US$1.513 trillion in value at current prices, while the oil sector contributed US$603.5 billion. As a result, the non-oil sector's share of the GCC's Gross Domestic Product (GDP) increased to 71.5% in 2023, up from 65% in 2022. This growth was supported by a 6.4% annual expansion in non-oil economic and insurance activities grew the fastest, with an 11.7% rise. Transport and storage followed closely at 11.6%. Real estate, public administration, trade, and education all recorded solid growth between 5.5% and 8.1%. Mining and quarrying, traditionally the largest contributor to the economy over the last five years (averaging 28.3% of GDP), declined sharply by 18.8%. Manufacturing, the largest non-oil sub-sector (11.7% average share), dipped slightly by 0.7%. GCC countries saw a decline in exports, with the total value of goods and services exported falling to US$1.259 trillion, a 7.1% decrease, representing 59.5% of the region's GDP at current prices. Final consumption expenditure rose 7.5% to US$1.245 trillion. Total capital formation, which includes investment in infrastructure and assets, grew 5.5% to US$601.8 billion. While falling oil revenues weighed on overall income levels, the continued expansion of the non-oil sector signals progress toward economic diversification across the GCC. Growth in services, finance, and trade indicate a shift away from traditional energy dependence, even as key oil-related industries showed signs of contraction.
